A5000997350- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Renal and related cancers
- Radiopharmaceutical Chemistry and Applications
- Economic and Financial Impacts of Cancer
- Cerebrovascular and Carotid Artery Diseases
- Cancer, Lipids, and Metabolism
- Urinary and Genital Oncology Studies
- Hormonal and reproductive studies
- Cancer survivorship and care
- Acute Ischemic Stroke Management
- Cancer Diagnosis and Treatment
- Congenital Diaphragmatic Hernia Studies
- Multiple and Secondary Primary Cancers
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Cardiovascular Health and Disease Prevention
- CAR-T cell therapy research
- Particle Detector Development and Performance
- Congenital Anomalies and Fetal Surgery
- Spinal Dysraphism and Malformations
University of California, San Francisco
1991-2025
Duke University
2013-2025
Quest Diagnostics (United States)
2025
UCSF Benioff Children's Hospital
2025
Duke Medical Center
2015-2024
Duke Cancer Institute
2015-2024
Prostate Cancer Foundation
2020-2024
St Thomas' Hospital
2023
Duke University Hospital
2012-2023
Cornell University
1998-2023
Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Patients Methods clear-cell mRCC previously treated agents targeting vascular endothelial growth factor pathway were randomly assigned (blinded ratio 1:1:1) to 0.3, 2, or 10 mg/kg intravenously...
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations the clinical management of patients with clear cell and non–clear renal carcinoma. These guidelines are developed by a panel leading experts from Member Institutions consisting medical oncologists, hematologists hematologic radiation urologists, pathologists. in continuous evolution updated annually or sometimes more often, if new high-quality data become available interim.
Abstract Purpose: Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell carcinoma (mRCC). We investigated immunomodulatory activity nivolumab hypothesis-generating prospective mRCC trial. Experimental Design: Nivolumab was administered intravenously every weeks at 0.3, 2, or 10 mg/kg to and treatment-naïve mRCC. Baseline on-treatment biopsies blood were obtained. Clinical...
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations the clinical management of patients with clear cell and non–clear renal carcinoma, are intended to assist decision-making. These Insights summarize Panel discussions 2020 update guidelines regarding initial first-line systemic therapy options advanced carcinoma.
To evaluate the safety and efficacy of gemcitabine cisplatin in combination with immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical cystectomy (RC) muscle-invasive bladder cancer.
CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and features mostly excluded from 3 trials. We report safety efficacy results the non-clear RCC (nccRCC) cohort 920.Patients advanced/metastatic nccRCC, Karnofsky performance status ≥70%, any International Metastatic Renal Cell Carcinoma Database Consortium risk received up to...
Transplantation of normal, immature, fetal hematopoietic cells into a preimmune recipient with congenital hemoglobinopathy may allow partial reconstitution normal hemoglobin production without the complications associated postnatal bone marrow transplantation (immunosuppression and occurrence graft versus host disease). In order to test this hypothesis naturally occurring polymorphism at β-hemoglobin locus sheep was used as marker for engraftment chimerism. Intraperitoneal injection...
This study investigated the influence of fetal environment on healing characteristics adult skin.The remarkable ability fetus to heal without scarring is poorly understood. The unique qualities wound may be caused by environment, tissues, or a combination both. There are numerous differences between prenatal and postnatal environments that play role in response injury.Full-thickness sheep skin was transplanted onto backs 60-day-gestation lambs (term, 145 days gestation). grafts were thus...
Background and Purpose —Percutaneous transluminal angioplasty (PTA) is currently being assessed for the treatment of carotid stenosis. In comparison with endarterectomy (CEA), there evidence an increased risk cerebral microembolism during procedure. We have sought any neuropsychological sequelae PTA compared it CEA to demonstrate relative safety 2 options. Methods —The outcomes after were in matched groups patients severe symptomatic stenosis, 96% whom had been randomized Carotid Vertebral...
Cystic epithelial lesions of the sellar and parasellar region are classified on basis histology location into Rathke's cleft cysts, epidermoid dermoid craniopharyngiomas. A retrospective review clinical presentation, radiological findings, was performed 19 such lesions, a survey literature pertinent to classification, embryology these conducted. Presentation nonspecific not predictive histology. Imaging studies were generally useful in distinguishing tumors, with exception suprasellar...
Radium-223 chloride ((223)Ra; Alpharadin) is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and excreted by the small intestine. When compared with beta-emitters (eg, strontium-89, samarium-153), (223)Ra delivers a high quantity energy per track length short tissue penetration.This review describes mechanism, radiobiology, preclinical development discusses clinical data currently available regarding its safety efficacy profile.Data from trials including...
Background Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B ) is a putative tumor suppressor, and preliminary evidence suggests LRP1B- mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI). Methods We conducted multicenter, retrospective pan-cancer analysis of patients alterations treated ICI at Duke University, Johns Hopkins University (JHU) Michigan (UM). The primary objective was to assess the association between overall response rate...
4513 Background: Patients (pts) with advanced renal cell carcinoma sarcomatoid features (sRCC) have poor prognosis and suboptimal outcomes anti-VEGF targeted therapy. Nivolumab plus ipilimumab (N+I) demonstrated superior objective response rate (ORR) overall survival (OS) vs sunitinib (S) in previously untreated pts International Metastatic RCC Database Consortium (IMDC) intermediate/poor (I/P)-risk, clear-cell, the phase 3 CheckMate 214 trial. Methods: We performed a post-hoc exploratory...
Patients with brain metastases from renal cell carcinoma (RCC) have been underrepresented in clinical trials, and effective systemic therapy is lacking. Cabozantinib shows robust activity metastatic RCC, but its effect on remains unclear.To assess the toxic effects of cabozantinib to treat patients RCC.This retrospective cohort study included RCC treated 15 international institutions (US, Belgium, France, Spain) between January 2014 October 2020. Cohort A comprised progressing without...